News
News
X
Phase 3 goal met by Novartis’ multiple myeloma drug
https://pharmaphorum.com/news/phase-3-goal-met-by-novartis-multiple-myeloma-drug/
X
Lilly’s depression drug fails to meet goal in phase 3
https://pharmaphorum.com/news/lilly-s-depression-drug-fails-to-meet-goal-in-phase-3/
X
Roche, Molecular Partners in cancer deal worth over $1 billion
https://pharmaphorum.com/news/roche-molecular-partners-in-cancer-deal-worth-over-1-billion/
X
Sanofi reports positive phase 3 insulin data
https://pharmaphorum.com/news/sanofi-reports-positive-phase-3-insulin-data/
X
Celgene, OncoMed sign $155m cancer deal
https://pharmaphorum.com/news/celgene-oncomed-sign-155m-cancer-deal/
X
Positive phase 3 for Novo Nordisk combination diabetes drug
https://pharmaphorum.com/news/positive-phase-3-for-novo-nordisk-combination-diabetes-drug/
X
Forest to acquire US rights to Merck’s schizophrenia drug
https://pharmaphorum.com/news/forest-to-acquire-us-rights-to-merck-s-schizophrenia-drug/
X
FDA extends review of Biogen’s haemophilia drug
https://pharmaphorum.com/news/fda-extends-review-of-biogen-s-haemophilia-drug/